NCT07506109: A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer
- State
- Under way
- Phase
- Phase 2
- People
- 49 planned
- Started
- 1 Mar 2026
- Primary completion
- Dec 2027
- Arms
- First-line cohort, Second-line cohort
- Results
- None posted
- 1 Mar 2026: Trial started
- 1 Apr 2026: Trial registered